Profound Medical (TSE:PRN) Trading Down 0.2% – Here’s What Happened

Posted by Jessica Moore on Oct 23rd, 2024

Shares of Profound Medical Corp. (TSE:PRN – Get Free Report) dropped 0.2% on Tuesday . The stock traded as low as C$10.30 and last traded at C$10.30. Approximately 9,329 shares were traded during mid-day trading, an increase of 33% from the average daily volume of 7,004 shares. The stock had previously closed at C$10.32.

Profound Medical Stock Down 0.2 %

The firm has a market capitalization of C$252.14 million, a PE ratio of -6.20 and a beta of 0.81. The firm’s 50 day moving average price is C$11.26 and its two-hundred day moving average price is C$11.56. The company has a quick ratio of 14.98, a current ratio of 8.61 and a debt-to-equity ratio of 16.95.

Profound Medical (TSE:PRN – Get Free Report) last announced its earnings results on Thursday, August 8th. The company reported C($0.38) earnings per share for the quarter, meeting the consensus estimate of C($0.38). The firm had revenue of C$3.06 million during the quarter, compared to analysts’ expectations of C$3.42 million. As a group, research analysts forecast that Profound Medical Corp. will post -1.9000001 EPS for the current fiscal year.

Insider Activity at Profound Medical

In related news, Senior Officer Rashed Osman Dewan purchased 9,765 shares of the business’s stock in a transaction that occurred on Thursday, August 15th. The shares were purchased at an average cost of C$12.85 per share, with a total value of C$125,480.25. 8.62% of the stock is currently owned by corporate insiders.

About Profound Medical

(Get Free Report)

Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum.